Torrent Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
3105.40 +10.60 (0.34%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
3075.05
Today’s High
3125.25
52 Week Low
2025
52 Week High
3589.95
3101.95 +7.10 (0.23%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
3076
Today’s High
3128
52 Week Low
2025.7
52 Week High
3590.7
Key Metrics
- Market Cap (In Cr) 104743.8
- Beta 0.49
- Div. Yield (%) 0.9
- P/B 15.28
- TTM P/E 63.78
- Peg Ratio 5.94
- Sector P/E 31.15
- D/E 0.42
- Open Price 3075.05
- Prev Close 3094.8
Torrent Pharmaceuticals Analysis
Price Analysis
-
1 Week-1.8%
-
3 Months-7.96%
-
6 Month15.41%
-
YTD34.23%
-
1 Year46.62%
Risk Meter
- 24% Low risk
- 24% Moderate risk
- 24% Balanced Risk
- 24% High risk
- 24% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 12
- 12
- 13
- 13
- Hold
- 6
- 6
- 6
- 6
- Sell
- 4
- 4
- 3
- 3
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 27
- 27
- 27
- 27
Torrent Pharmaceuticals News
Home remedy: Indian pharma bets on domestic brands to fight US generics slowdown
4 min read . 08 Nov 2024Torrent Pharmaceuticals Q2 Results Live: Profit Rises by 17.36% YoY
1 min read . 26 Oct 2024Stock market today: Experts recommend four stocks to buy or sell on Tuesday
5 min read . 22 Oct 2024Torrent Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 10728
- Selling/ General/ Admin Expenses Total
- 1984
- Depreciation/ Amortization
- 808
- Other Operating Expenses Total
- 2690
- Total Operating Expense
- 8080
- Operating Income
- 2648
- Net Income Before Taxes
- 2352
- Net Income
- 1656
- Diluted Normalized EPS
- 47.11
- Period
- 2024
- Total Assets
- 15061
- Total Liabilities
- 8205
- Total Equity
- 6856
- Tangible Book Valueper Share Common Eq
- 57.17
- Period
- 2024
- Cashfrom Operating Activities
- 3266
- Cashfrom Investing Activities
- -168
- Cashfrom Financing Activities
- -2779
- Net Changein Cash
- 327
- Period
- 2023
- Total Revenue
- 9620.15
- Selling/ General/ Admin Expenses Total
- 3447.24
- Depreciation/ Amortization
- 702.03
- Other Operating Expenses Total
- 471.9
- Total Operating Expense
- 7484.69
- Operating Income
- 2135.46
- Net Income Before Taxes
- 1847.16
- Net Income
- 1245.23
- Diluted Normalized EPS
- 36.45
- Period
- 2023
- Total Assets
- 15011.85
- Total Liabilities
- 8813.78
- Total Equity
- 6198.07
- Tangible Book Valueper Share Common Eq
- 22.78
- Period
- 2023
- Cashfrom Operating Activities
- 2426.96
- Cashfrom Investing Activities
- -2415.31
- Cashfrom Financing Activities
- 77.36
- Net Changein Cash
- 110.13
- Period
- 2022
- Total Revenue
- 8508.04
- Selling/ General/ Admin Expenses Total
- 3060.61
- Depreciation/ Amortization
- 661.93
- Other Operating Expenses Total
- 440.04
- Total Operating Expense
- 7223.63
- Operating Income
- 1284.41
- Net Income Before Taxes
- 1225.91
- Net Income
- 777.18
- Diluted Normalized EPS
- 32.05
- Period
- 2022
- Total Assets
- 13099.84
- Total Liabilities
- 7146.89
- Total Equity
- 5952.95
- Tangible Book Valueper Share Common Eq
- 63.45
- Period
- 2022
- Cashfrom Operating Activities
- 1802.99
- Cashfrom Investing Activities
- -196.63
- Cashfrom Financing Activities
- -1781.05
- Net Changein Cash
- -174.16
- Period
- 2021
- Total Revenue
- 8004.83
- Selling/ General/ Admin Expenses Total
- 2822.98
- Depreciation/ Amortization
- 657.31
- Other Operating Expenses Total
- 435.69
- Total Operating Expense
- 6176.94
- Operating Income
- 1827.89
- Net Income Before Taxes
- 1526.26
- Net Income
- 1251.88
- Diluted Normalized EPS
- 37
- Period
- 2021
- Total Assets
- 14074.65
- Total Liabilities
- 8237.48
- Total Equity
- 5837.17
- Tangible Book Valueper Share Common Eq
- 44.67
- Period
- 2021
- Cashfrom Operating Activities
- 2005.35
- Cashfrom Investing Activities
- -449.42
- Cashfrom Financing Activities
- -1650.79
- Net Changein Cash
- -89.26
- Period
- 2020
- Total Revenue
- 7939.31
- Selling/ General/ Admin Expenses Total
- 2908.94
- Depreciation/ Amortization
- 651.51
- Other Operating Expenses Total
- 514.98
- Total Operating Expense
- 6423.33
- Operating Income
- 1515.98
- Net Income Before Taxes
- 1186.57
- Net Income
- 1024.72
- Diluted Normalized EPS
- 28.79
- Period
- 2020
- Total Assets
- 14009.74
- Total Liabilities
- 9186.52
- Total Equity
- 4823.22
- Tangible Book Valueper Share Common Eq
- 3.19
- Period
- 2020
- Cashfrom Operating Activities
- 1392.91
- Cashfrom Investing Activities
- 198.61
- Cashfrom Financing Activities
- -1549.04
- Net Changein Cash
- 73.06
- Period
- 2019
- Total Revenue
- 7672.8
- Selling/ General/ Admin Expenses Total
- 2897.84
- Depreciation/ Amortization
- 614.39
- Other Operating Expenses Total
- 470.23
- Total Operating Expense
- 6664.44
- Operating Income
- 1008.36
- Net Income Before Taxes
- 561.66
- Net Income
- 436.28
- Diluted Normalized EPS
- 21.16
- Period
- 2019
- Total Assets
- 14120.92
- Total Liabilities
- 9396.57
- Total Equity
- 4724.35
- Tangible Book Valueper Share Common Eq
- -10.65
- Period
- 2019
- Cashfrom Operating Activities
- 1798.08
- Cashfrom Investing Activities
- -241.28
- Cashfrom Financing Activities
- -1314.45
- Net Changein Cash
- 238.02
- Period
- 2018
- Total Revenue
- 5949.83
- Selling/ General/ Admin Expenses Total
- 2421.14
- Depreciation/ Amortization
- 408.6
- Other Operating Expenses Total
- 402.62
- Total Operating Expense
- 5009.18
- Operating Income
- 940.65
- Net Income Before Taxes
- 931.01
- Net Income
- 678.11
- Diluted Normalized EPS
- 20.04
- Period
- 2018
- Total Assets
- 14243.22
- Total Liabilities
- 9621.03
- Total Equity
- 4622.19
- Tangible Book Valueper Share Common Eq
- -30.71
- Period
- 2018
- Cashfrom Operating Activities
- 899.42
- Cashfrom Investing Activities
- -4706.95
- Cashfrom Financing Activities
- 3417.39
- Net Changein Cash
- -365.5
- Period
- 2024-09-30
- Total Revenue
- 2889
- Selling/ General/ Admin Expenses Total
- 543
- Depreciation/ Amortization
- 198
- Other Operating Expenses Total
- 729
- Total Operating Expense
- 2148
- Operating Income
- 741
- Net Income Before Taxes
- 661
- Net Income
- 453
- Diluted Normalized EPS
- 13.37
- Period
- 2024-09-30
- Total Assets
- 15088
- Total Liabilities
- 7584
- Total Equity
- 7504
- Tangible Book Valueper Share Common Eq
- 83.65
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1683
- Cashfrom Investing Activities
- -159
- Cashfrom Financing Activities
- -1215
- Net Changein Cash
- 311
- Period
- 2024-06-30
- Total Revenue
- 2859
- Selling/ General/ Admin Expenses Total
- 550
- Depreciation/ Amortization
- 197
- Other Operating Expenses Total
- 711
- Total Operating Expense
- 2152
- Operating Income
- 707
- Net Income Before Taxes
- 656
- Net Income
- 457
- Diluted Normalized EPS
- 13.51
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2745
- Selling/ General/ Admin Expenses Total
- 486
- Depreciation/ Amortization
- 203
- Other Operating Expenses Total
- 697
- Total Operating Expense
- 2065
- Operating Income
- 680
- Net Income Before Taxes
- 631
- Net Income
- 449
- Diluted Normalized EPS
- 13.27
- Period
- 2024-03-31
- Total Assets
- 15061
- Total Liabilities
- 8205
- Total Equity
- 6856
- Tangible Book Valueper Share Common Eq
- 57.17
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 3266
- Cashfrom Investing Activities
- -168
- Cashfrom Financing Activities
- -2779
- Net Changein Cash
- 327
- Period
- 2023-12-31
- Total Revenue
- 2732
- Selling/ General/ Admin Expenses Total
- 496
- Depreciation/ Amortization
- 213
- Other Operating Expenses Total
- 670
- Total Operating Expense
- 1988
- Operating Income
- 744
- Net Income Before Taxes
- 631
- Net Income
- 443
- Diluted Normalized EPS
- 11.27
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 2660
- Selling/ General/ Admin Expenses Total
- 503
- Depreciation/ Amortization
- 201
- Other Operating Expenses Total
- 672
- Total Operating Expense
- 2036
- Operating Income
- 624
- Net Income Before Taxes
- 559
- Net Income
- 386
- Diluted Normalized EPS
- 11.39
- Period
- 2023-09-30
- Total Assets
- 14744
- Total Liabilities
- 8037
- Total Equity
- 6707
- Tangible Book Valueper Share Common Eq
- 45.21
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 1540
- Cashfrom Investing Activities
- -166
- Cashfrom Financing Activities
- -1344
- Net Changein Cash
- 30
- Period
- 2023-06-30
- Total Revenue
- 2591
- Selling/ General/ Admin Expenses Total
- 499
- Depreciation/ Amortization
- 191
- Other Operating Expenses Total
- 651
- Total Operating Expense
- 1991
- Operating Income
- 600
- Net Income Before Taxes
- 531
- Net Income
- 378
- Diluted Normalized EPS
- 11.18
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 2491.15
- Selling/ General/ Admin Expenses Total
- 440.69
- Depreciation/ Amortization
- 195.59
- Other Operating Expenses Total
- 619.22
- Total Operating Expense
- 1959.69
- Operating Income
- 531.46
- Net Income Before Taxes
- 433.16
- Net Income
- 296.23
- Diluted Normalized EPS
- 8.77
- Period
- 2023-03-31
- Total Assets
- 15011.85
- Total Liabilities
- 8813.78
- Total Equity
- 6198.07
- Tangible Book Valueper Share Common Eq
- 22.78
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2426.96
- Cashfrom Investing Activities
- -2415.31
- Cashfrom Financing Activities
- 77.36
- Net Changein Cash
- 110.13
- Period
- 2022-12-31
- Total Revenue
- 2491
- Selling/ General/ Admin Expenses Total
- 423
- Depreciation/ Amortization
- 193
- Other Operating Expenses Total
- 614
- Total Operating Expense
- 1960
- Operating Income
- 531
- Net Income Before Taxes
- 419
- Net Income
- 283
- Diluted Normalized EPS
- 8.36
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Torrent Pharmaceuticals Technical
Moving Average
SMA
- 5 Day3126.58
- 10 Day3158.15
- 20 Day3222.97
- 50 Day3358.17
- 100 Day3246.8
- 300 Day2945.83
Torrent Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Divis Laboratories
- 5960
- 63.85
- 1.08
- 6276.2
- 3350.05
- 158219.27
- Cipla
- 1463
- -8.35
- -0.57
- 1702
- 1165.1
- 118121.88
- Torrent Pharmaceuticals
- 3105.4
- 10.6
- 0.34
- 3589.95
- 2025
- 105105.37
- Dr Reddys Laboratories
- 1194.55
- -19.4
- -1.6
- 1420.2
- 1074.35
- 19892.66
- Zydus Lifesciences
- 942
- -4.9
- -0.52
- 1323.9
- 628.05
- 94765.2
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Divis Laboratories
- 97.72
- 11.54
- 18.97
- 26.38
- Cipla
- 27.37
- 4.45
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 65.33
- 15.28
- 20.64
- 13.18
- Dr Reddys Laboratories
- 18.36
- 3.58
- 16.73
- 14.63
- Zydus Lifesciences
- 24.99
- 4.81
- 15.65
- 14.33
Torrent Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 25-Oct-24
- Quarterly Results
- 23-Jul-24
- Quarterly Results
- 24-May-24
- Audited Results & Final Dividend
- 02-Feb-24
- Quarterly Results & Interim Dividend
- 23-Oct-23
- Quarterly Results
- 07-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results & Final Dividend
- 25-Jan-23
- Quarterly Results & Interim Dividend
- 21-Oct-22
- Quarterly Results
- 29-Jul-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Nov-23
- 26-Oct-23
- POM
- 07-Aug-23
- 20-Jun-23
- AGM
- 29-Jul-22
- 25-May-22
- AGM
- 27-Jul-21
- 30-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 24-May-24
- 21-Jun-24
- 21-Jun-24
- 6
- 12-Jan-24
- 12-Feb-24
- 12-Feb-24
- 22
- 30-May-23
- 23-Jun-23
- 23-Jun-23
- 8
- 12-Jan-23
- 03-Feb-23
- 03-Feb-23
- 14
- 25-May-22
- 06-Jun-22
- 03-Jun-22
- 8
- 26-May-22
- 06-Jun-22
- 03-Jun-22
- 15
- 10-Jan-22
- 03-Feb-22
- 02-Feb-22
- 25
- 18-May-21
- 18-Jun-21
- 17-Jun-21
- 15
- 18-Jan-21
- 16-Feb-21
- 15-Feb-21
- 20
- Announced on
- Record Date
- Ex-Bonus
- Description
- 25-May-22
- 11-Jul-22
- 08-Jul-22
- Bonus issue of equity shares in the ratio of 1:1 of Rs. 5/-.